<DOC>
	<DOCNO>NCT02600143</DOCNO>
	<brief_summary>The aim trial identify biomarkers genetic predisposition development immune checkpoint relate colitis .</brief_summary>
	<brief_title>Identification Predictive Parameters Colitis Melanoma Patients Treated With Immunotherapy .</brief_title>
	<detailed_description>Immunotherapy immune checkpoint-inhibitors standard treatment patient melanoma . However , 15 % patient treat Ipilimumab grade 3-4 colitis occur . In programmed cell death protein 1 ( PD1 ) inhibitor colitis also see adverse event , although less prominent . We want find good predictive biomarker select patient prone colitis.So far test available might predictive whether patient develop grade 3-4 colitis . The study consist four part : 1 . ) identify genetic profile associate ipilimumab-induced colitis , 2 . ) identify predictive ( serum fecal ) biomarkers ipilimumab-induced colitis , 3 . ) study tissue ipilimumab-induced colitis 4 ) study role gut microbiome development colitis . Patients able participate one , part study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Patients melanoma treat immune checkpoint inhibitor ( ipilimumab , nivolumab , pembrolizumab ) 2 . Signed write informed consent . 3 . Able comply protocol . 1 . Patients preexist colitis ( e.g . Crohn 's disease , ulcerative colitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Colitis</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Pembrolizumab</keyword>
</DOC>